CN-122025094-A - SLE curative effect dynamic monitoring and prognosis evaluation system for rheumatism immunology

CN122025094ACN 122025094 ACN122025094 ACN 122025094ACN-122025094-A

Abstract

The invention relates to the technical field of medical monitoring and evaluation, and particularly discloses a SLE curative effect dynamic monitoring and prognosis evaluation system for a rheumatism immunological department, which comprises a diagnosis phenomenon judging module, a complement tracing scoring module, a complement correlation analysis module, a scoring multidimensional correcting module and a scoring multidimensional correcting module, wherein the diagnosis phenomenon judging module is used for carrying out double-dimensional antibody protein curative effect diagnosis and serum clinical consistency judgment, the complement tracing scoring module is used for carrying out disease tracing analysis, determining the original category of a phenomenon and a current target monitoring object, calculating a prognosis initial score, the complement correlation analysis module is used for carrying out double-core index regulation correlation analysis of complement C3, determining the periodical stability of an inconsistent event according to the change trend analysis of the concentration of the complement C3, and carrying out prognosis initial scoring correction by combining time sequence dynamic change and periodical stability, so that the system can effectively eliminate false index interference, and remarkably improve the specificity of SLE curative effect monitoring and the accuracy of prognosis evaluation.

Inventors

XU SHUIMING
YANG QINGYUAN
LIU NAN
Xu Junlai
ZENG GUOXING

Assignees

赣州市立医院

Dates

Publication Date: 20260512
Application Date: 20260127

Claims (10)

1. A SLE curative effect dynamic monitoring and prognosis evaluation system for rheumatism immunology is characterized by comprising: The diagnosis phenomenon judging module is used for acquiring current diagnosis and treatment data of SLE patients, diagnosing the curative effect through the double-dimensional antibody protein and judging the clinical consistency of serum; the complement tracing scoring module is used for collecting complement C3 of SLE patients in real time if serum clinical inconsistency exists, determining the original category of the phenomenon and the current target monitoring object through disease evidence tracing analysis, and calculating the prognosis initial score; The complement correlation analysis module is used for acquiring SLE patient historical diagnosis and treatment data based on the original category of the phenomenon, determining the regulation and control correlation of the concentration of complement C3 and the dual-core index through the dual-core index regulation and control correlation analysis of the complement C3, and determining the periodic stability of inconsistent events according to the change trend analysis of the concentration of the complement C3; and the grading multidimensional correction module is used for carrying out prognosis initial grading correction based on the periodical stability of the inconsistent event and combining the analysis of the variation trend of the concentration of ds-DNA antibody and the urine protein quantification.
2. The SLE efficacy dynamic monitoring and prognosis evaluation system for rheumatic immunology according to claim 1, wherein the diagnosis of efficacy of the protein by the two-dimensional antibody and the determination of clinical consistency of serum are: Calculating the difference ratio of the current ds-DNA antibody concentration to the initial ds-DNA concentration to obtain the antibody relieving amplitude; Calculating the difference ratio of the current urine protein ration and the initial urine protein ration to obtain the urine protein alleviation amplitude; if the magnitude of antibody alleviation is greater than the magnitude of antibody alleviation standard, then SLE therapeutic effect alleviation of ds-DNA concentration is demonstrated; on the contrary, it indicates that SLE efficacy at ds-DNA concentration is not alleviated; If the urine protein alleviation amplitude is greater than the urine protein alleviation amplitude standard, the SLE curative effect of urine protein quantification is relieved; Otherwise, it indicates that the efficacy of urine protein quantification SLE is not relieved; If the therapeutic diagnosis of ds-DNA antibody concentration is not the same as that of urine protein quantification, the clinical inconsistency of serum is judged.
3. The SLE efficacy dynamic monitoring and prognosis evaluation system for rheumatic immunology according to claim 1, wherein the determining of the original category of phenomenon and the current targeting of the monitored object is: If the concentration of complement C3 is greater than or equal to the threshold value of the concentration of complement C3, the actual condition of the SLE patient is the alleviation of the curative effect of SLE; otherwise, the actual condition of the SLE patient is indicated to be that the SLE curative effect is not relieved; if the therapeutic diagnosis of ds-DNA antibody concentration is the same as the real illness state of SLE patient, judging that the original type of phenomenon is the false type of antibody, and the current target monitoring object is urine protein quantification and complement C3 concentration; if the therapeutic effect diagnosis of urine protein quantification is the same as the real illness state of SLE patient, judging that the original type of phenomenon is urine protein pseudotype, and the current target monitoring object is ds-DNA antibody concentration and complement C3 concentration.
4. The SLE efficacy dynamic monitoring and prognosis evaluation system for rheumatic immunology according to claim 1, wherein the process of calculating the prognosis initial score is: When the original class of phenomenon is an antibody pseudo class: calculating the product of the antibody relieving amplitude and the score of 100 to obtain a prognosis initial score; When the phenomenon origin category is the urine protein pseudotype: and calculating the product of the urine protein alleviation amplitude and the score of 100 to obtain the initial prognosis score.
5. The SLE efficacy dynamic monitoring and prognosis evaluation system for rheumatic immunology according to claim 1, wherein the dual-core index regulation and control correlation analysis of complement C3 is characterized in that the process for determining the regulation and control correlation of the concentration of complement C3 and the dual-core index is as follows: the double-core index refers to ds-DNA antibody concentration and urine protein quantification; Based on SLE patient historical diagnosis and treatment data, respectively performing time sequence integration on complement C3 concentration, ds-DNA antibody concentration and urine protein quantification, and performing normalization treatment by adopting Z-score standardization to obtain a complement sequence, an antibody sequence and a urine protein sequence; Calculating a correlation coefficient r1 of the concentration of complement C3 and the concentration of ds-DNA antibody and a correlation coefficient r2 of the concentration of complement C3 and the quantitative urine protein by adopting Spearman rank correlation analysis; if r1 and r2 are negative values, the negative correlation exists between the concentration of complement C3 and the concentration of ds-DNA antibody and the quantitative presence of urine protein; if r1 and r2 are positive values, this indicates that there is a positive correlation between complement C3 concentration and ds-DNA antibody concentration, and urine protein quantification.
6. The SLE efficacy dynamic monitoring and prognosis evaluation system for rheumatic immunology according to claim 1, wherein the analysis of the trend of complement C3 concentration is as follows: Analyzing the change trend of the concentration of the complement C3 by adopting a time sequence physiological index dynamic rate analysis method to obtain the current change rate of the concentration of the complement, and specifically comprising the following steps: Based on SLE patient historical diagnosis and treatment data, marking the historical diagnosis and treatment data with serum clinical inconsistencies as phenomenon analysis diagnosis and treatment data; Extracting the concentration of complement C3 in the phenomenon analysis diagnosis and treatment data, and carrying out time sequence integration to obtain a phenomenon analysis complement sequence; Calculating the concentration difference of complement C3 between the later monitoring point and the former monitoring point in the phenomenon analysis complement sequence to obtain a complement concentration difference; performing ratio processing on the complement concentration difference value and the monitoring period to obtain the complement concentration change rate of the phenomenon analysis diagnosis and treatment data; The monitoring period refers to the time interval between two monitoring points; And carrying out average treatment on the complement concentration change rate of the phenomenon analysis diagnosis and treatment data to obtain the current complement concentration change rate.
7. The SLE efficacy dynamic monitoring and prognosis evaluation system for rheumatic immunology according to claim 1, wherein the process of determining the cyclical stability of inconsistent events is: analyzing diagnosis and treatment data based on any phenomenon in SLE patient historical diagnosis and treatment data: extracting monitoring points with clinical inconsistency of serum, and marking the monitoring points as the pseudo-antibody monitoring points if the monitoring points are pseudo-antibody types; Extracting monitoring points with clinical inconsistency of serum, and marking the monitoring points as urine protein false monitoring points if the monitoring points are urine protein false types; Respectively calculating the number of the false monitoring points of the antibody and the ratio of the number of the false monitoring points of the urine protein in the number of the total monitoring points to obtain the antibody ratio and the urine protein ratio of the diagnosis and treatment data of the phenomenon analysis; respectively calculating the average value of the antibody ratio and the urine protein ratio to obtain the antibody persistence and the urine protein persistence; And respectively calculating the variation coefficients of the antibody ratio and the urine protein ratio to obtain the antibody deviation degree and the urine protein deviation degree.
8. The SLE efficacy dynamic monitoring and prognosis evaluation system for rheumatic immunology according to claim 6, wherein the analysis of the trend of the ds-DNA antibody concentration and urine protein quantification is as follows: And analyzing the change trend of the ds-DNA antibody concentration and urine protein quantification by adopting a time sequence physiological index dynamic rate analysis method to obtain the current antibody concentration change rate and the current urine protein change rate.
9. The SLE efficacy dynamic monitoring and prognosis evaluation system for rheumatic immunology according to claim 1, wherein the process of performing the prognosis initial score correction is: When the original phenomenon category is an antibody false category, the index association correction coefficient is r2; Periodic stability correction coefficient = antibody duration x (1-antibody bias); when the original category of the phenomenon is a urine protein false category, the index association correction coefficient is r1; periodic stability correction coefficient = urinary protein duration x (1-urinary protein deviation); calculating a time sequence dynamic correction coefficient beta according to the ds-DNA antibody concentration and urine protein quantitative change trend analysis; final prognosis score = initial prognosis score Index-related correction coefficient Dynamic time sequence correction coefficient beta The periodic stability correction coefficient.
10. The SLE efficacy dynamic monitoring and prognosis evaluation system for rheumatic immunology according to claim 9, wherein the process of calculating the time sequence dynamic correction coefficient beta according to the analysis of the change trend of ds-DNA antibody concentration and urine protein quantification is: : wherein, beta refers to a time sequence dynamic correction coefficient, R1 refers to a current complement concentration change rate, R2 refers to a current antibody concentration change rate, and R3 refers to a current urine protein change rate.

Description

SLE curative effect dynamic monitoring and prognosis evaluation system for rheumatism immunology Technical Field The invention relates to the technical field of medical monitoring and evaluation, in particular to a SLE curative effect dynamic monitoring and prognosis evaluation system for a rheumatism immunological department. Background In clinical diagnosis and treatment of Systemic Lupus Erythematosus (SLE), along with standardization of clinical detection technology and perfection of diagnosis and treatment guidelines, the existing curative effect monitoring and prognosis evaluation technology can provide objective basis for treatment effect and adjustment of treatment schemes, and becomes more important. However, the prior art still has the key problem of insufficient pertinence, and is difficult to meet the requirements of SLE accurate diagnosis and treatment, on one hand, the existing assessment method does not solve the core pain point of serology-clinical inconsistency, when ds-DNA antibody concentration is contrary to urine protein quantitative curative effect diagnosis results, false index interference cannot be distinguished, illness state misjudgment is easily caused, on the other hand, the prior art relies on index static analysis of single time point, the period stability of pathological regulation association and inconsistent events is not fully analyzed, the prognosis assessment lacks multidimensional calibration, random fluctuation interference is difficult to remove, and finally the problems of low dynamic monitoring efficiency of curative effect and inaccurate prognosis assessment are caused. Therefore, the invention provides a SLE curative effect dynamic monitoring and prognosis evaluation system for the rheumatics department. Disclosure of Invention The invention aims to provide a SLE curative effect dynamic monitoring and prognosis evaluation system for the department of rheumatics, so as to solve the problems in the background. The aim of the invention can be achieved by the following technical scheme: A SLE efficacy dynamic monitoring and prognostic evaluation system for use in the rheumatiidae department, comprising: The diagnosis phenomenon judging module is used for acquiring current diagnosis and treatment data of SLE patients, diagnosing the curative effect through the double-dimensional antibody protein and judging the clinical consistency of serum; the complement tracing scoring module is used for collecting complement C3 of SLE patients in real time if serum clinical inconsistency exists, determining the original category of the phenomenon and the current target monitoring object through disease evidence tracing analysis, and calculating the prognosis initial score; The complement correlation analysis module is used for acquiring SLE patient historical diagnosis and treatment data based on the original category of the phenomenon, determining the regulation and control correlation of the concentration of complement C3 and the dual-core index through the dual-core index regulation and control correlation analysis of the complement C3, and determining the periodic stability of inconsistent events according to the change trend analysis of the concentration of the complement C3; and the grading multidimensional correction module is used for carrying out prognosis initial grading correction based on the periodical stability of the inconsistent event and combining the analysis of the variation trend of the concentration of ds-DNA antibody and the urine protein quantification. As a further scheme of the invention: Further, the process of diagnosing the curative effect of the double-dimensional antibody protein and judging the clinical consistency of the serum is as follows: Calculating the difference ratio of the current ds-DNA antibody concentration to the initial ds-DNA concentration to obtain the antibody relieving amplitude; Calculating the difference ratio of the current urine protein ration and the initial urine protein ration to obtain the urine protein alleviation amplitude; if the magnitude of antibody alleviation is greater than the magnitude of antibody alleviation standard, then SLE therapeutic effect alleviation of ds-DNA concentration is demonstrated; on the contrary, it indicates that SLE efficacy at ds-DNA concentration is not alleviated; If the urine protein alleviation amplitude is greater than the urine protein alleviation amplitude standard, the SLE curative effect of urine protein quantification is relieved; Otherwise, it indicates that the efficacy of urine protein quantification SLE is not relieved; If the therapeutic diagnosis of ds-DNA antibody concentration is not the same as that of urine protein quantification, the clinical inconsistency of serum is judged. Further, the process of determining the original category of the phenomenon and the current target monitoring object is as follows: If the concentration of complement C3 is greater than or equal to the